Teacher:In this task, you're given a paragraph and title from the research paper. Your task is to classify whether the given title is suitable or not for the research paper based on the given paragraph. Return "True" if title is proper according to paragraph else "False".
Teacher: Now, understand the problem? Solve this instance: Paragraph: Background: DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO 2 -powered BiojectorH device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity. Methods: Forty adults, 18-50 years, were randomly assigned to intramuscular (IM) vaccinations with DNA vaccine, VRC-HIVDNA016-00-VP, (weeks 0, 4, 8) by BiojectorH 2000 TM or needle and syringe (N/S) and boosted IM at week 24 with VRC-HIVADV014-00-VP (rAd5) with N/S at 10 10 or 10 11 particle units (PU). Equal numbers per assigned schedule had low (#500) or high (.500) reciprocal titers of preexisting Ad5 neutralizing antibody. Results: 120 DNA and 39 rAd5 injections were given; 36 subjects completed follow-up research sample collections. IFN-c ELISpot response rates were 17/19 (89%) for BiojectorH and 13/17 (76%) for N/S delivery at Week 28 (4 weeks post rAd5 boost). The magnitude of ELISpot response was about 3-fold higher in BiojectorH compared to N/S groups. Similar effects on response rates and magnitude were observed for CD8+, but not CD4+ T-cell responses by ICS. Env-specific antibody responses were about 10-fold higher in Biojector-primed subjects. Conclusions: DNA vaccination by BiojectorH was well-tolerated and compared to needle injection, primed for greater IFN-c ELISpot, CD8+ T-cell, and antibody responses after rAd5 boosting.
Title: DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T- Cell Responses after rAd5 Boost in a Randomized Clinical Trial
Student:
True